VWM
ACAD icon

Vermillion Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Vermillion Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$312 – 1531
2026
Q1 		$312 Buy
+14
New +$335 ﹤0.01% 1169

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vermillion Wealth Management's ACAD Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 14 shares — an estimated $312 sold.

Vermillion Wealth Management first reported a position in ACAD in Q1 2026 and held it in 1 quarter. The position peaked at $312 in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 14 Acadia Pharmaceuticals shares in Q2 2026, an estimated $312.
  • Vermillion Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Acadia Pharmaceuticals position peaked at $312 in Q1 2026.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.